349 related articles for article (PubMed ID: 22886474)
21. Macrophage activation syndrome in 13 children with systemic-onset juvenile idiopathic arthritis.
Zeng HS; Xiong XY; Wei YD; Wang HW; Luo XP
World J Pediatr; 2008 May; 4(2):97-101. PubMed ID: 18661762
[TBL] [Abstract][Full Text] [Related]
22. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
Lee PY; Schulert GS; Canna SW; Huang Y; Sundel J; Li Y; Hoyt KJ; Blaustein RB; Wactor A; Do T; Halyabar O; Chang MH; Dedeoglu F; Case SM; Meidan E; Lo MS; Sundel RP; Richardson ET; Newburger JW; Hershfield MS; Son MB; Henderson LA; Nigrovic PA
Ann Rheum Dis; 2020 Feb; 79(2):225-231. PubMed ID: 31707357
[TBL] [Abstract][Full Text] [Related]
23. Macrophage activation syndrome as a complication of rheumatologic disorders, a report from Iran.
Assari R; Sadeghi P; Mirmohammadsadeghi A; Ebadi F; Ziaee V
Reumatismo; 2020 Jan; 71(4):189-198. PubMed ID: 31995957
[TBL] [Abstract][Full Text] [Related]
24. The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus.
Bobek D; Grčević D; Kovačić N; Lukić IK; Jelušić M
Pediatr Rheumatol Online J; 2014; 12():50. PubMed ID: 25516724
[TBL] [Abstract][Full Text] [Related]
25. Macrophage activation syndrome triggered by systemic lupus erythematosus flare: successful treatment with a combination of dexamethasone sodium phosphate, intravenous immunoglobulin, and cyclosporine: a case report.
Gouda W; Alsaqabi F; Moshrif A; Abbas AS; Abdel-Aziz TM; Islam MA
J Med Case Rep; 2021 Oct; 15(1):497. PubMed ID: 34620236
[TBL] [Abstract][Full Text] [Related]
26. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients.
Gavand PE; Serio I; Arnaud L; Costedoat-Chalumeau N; Carvelli J; Dossier A; Hinschberger O; Mouthon L; Le Guern V; Korganow AS; Poindron V; Gourguechon C; Lavigne C; Maurier F; Labro G; Heymonet M; Artifoni M; Viau AB; Deligny C; Sene T; Terriou L; Sibilia J; Mathian A; Bloch-Queyrat C; Larroche C; Amoura Z; Martin T
Autoimmun Rev; 2017 Jul; 16(7):743-749. PubMed ID: 28483541
[TBL] [Abstract][Full Text] [Related]
27. Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China.
Zou LX; Zhu Y; Sun L; Ma HH; Yang SR; Zeng HS; Xiao JH; Yu HG; Guo L; Xu YP; Lu MP
World J Pediatr; 2020 Feb; 16(1):89-98. PubMed ID: 31612427
[TBL] [Abstract][Full Text] [Related]
28. Rhupus syndrome in children: A multi-center retrospective cohort study and literature review.
Sener S; Batu ED; Sahin S; Yildirim DG; Ekinci MK; Kisaoglu H; Karali Y; Demir S; Kaya Akca U; Gunalp A; Turkmen S; Kavrul Kayaalp G; Arslanoglu C; Torun R; Basaran O; Pac Kisaarslan A; Sozeri B; Aktay Ayaz N; Bakkaloglu SA; Kilic SS; Kalyoncu M; Bilginer Y; Unsal E; Kasapcopur O; Ozen S
Lupus; 2024 Mar; 33(3):273-281. PubMed ID: 38226485
[TBL] [Abstract][Full Text] [Related]
29. Macrophage activation syndrome as the initial manifestation of severe juvenile onset systemic lupus erythematosus. Favorable response to cyclophosphamide.
Torres Jiménez A; Solís Vallejo E; Zeferino Cruz M; Céspedes Cruz A; Sánchez Jara B
Reumatol Clin; 2014; 10(5):331-5. PubMed ID: 24035795
[TBL] [Abstract][Full Text] [Related]
30. Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis during tocilizumab therapy.
Irabu H; Shimizu M; Kaneko S; Inoue N; Mizuta M; Nakagishi Y; Yachie A
Pediatr Res; 2020 Dec; 88(6):934-939. PubMed ID: 32184444
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome.
Mizuta M; Shimizu M; Inoue N; Nakagishi Y; Yachie A
Cytokine; 2019 Jul; 119():182-187. PubMed ID: 30952065
[TBL] [Abstract][Full Text] [Related]
32. Macrophage activation syndrome in pediatrics: 10 years data from an Indian center.
Pal P; Bathia J; Giri PP; Roy M; Nandi A
Int J Rheum Dis; 2020 Oct; 23(10):1412-1416. PubMed ID: 32666639
[TBL] [Abstract][Full Text] [Related]
33. [Macrophage activation syndrome in Chinese children with systemic onset juvenile idiopathic arthritis].
Li CF; He XH; Kuang WY; Han TX; Zhou YF
Zhonghua Er Ke Za Zhi; 2006 Nov; 44(11):806-11. PubMed ID: 17274865
[TBL] [Abstract][Full Text] [Related]
34. Clinical features and correct diagnosis of macrophage activation syndrome.
Cron RQ; Davi S; Minoia F; Ravelli A
Expert Rev Clin Immunol; 2015; 11(9):1043-53. PubMed ID: 26082353
[TBL] [Abstract][Full Text] [Related]
35. Thrombotic Microangiopathy Associated with Macrophage Activation Syndrome: A Multinational Study of 23 Patients.
Minoia F; Tibaldi J; Muratore V; Gallizzi R; Bracaglia C; Arduini A; Comak E; Vougiouka O; Trauzeddel R; Filocamo G; Mastrangelo A; Micalizzi C; Kasapcopur O; Unsal E; Kitoh T; Tsitsami E; Kostik M; Schmid JP; Prader S; Laube G; Maritsi D; Jelusic M; Shenoi S; Vastert S; Ardissino G; Cron RQ; Ravelli A;
J Pediatr; 2021 Aug; 235():196-202. PubMed ID: 33836183
[TBL] [Abstract][Full Text] [Related]
36. Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis.
Schulert GS; Minoia F; Bohnsack J; Cron RQ; Hashad S; KonÉ-Paut I; Kostik M; Lovell D; Maritsi D; Nigrovic PA; Pal P; Ravelli A; Shimizu M; Stanevicha V; Vastert S; Woerner A; de Benedetti F; Grom AA
Arthritis Care Res (Hoboken); 2018 Mar; 70(3):409-419. PubMed ID: 28499329
[TBL] [Abstract][Full Text] [Related]
37. Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
Takakura M; Shimizu M; Irabu H; Sakumura N; Inoue N; Mizuta M; Nakagishi Y; Yachie A
Clin Immunol; 2019 Nov; 208():108252. PubMed ID: 31449879
[TBL] [Abstract][Full Text] [Related]
38. Serum thrombomodulin in systemic lupus erythematosus and juvenile idiopathic arthritis.
el-Gamal YM; Heshmat NM; el-Kerdany TH; Fawzy AF
Pediatr Allergy Immunol; 2004 Jun; 15(3):270-7. PubMed ID: 15209962
[TBL] [Abstract][Full Text] [Related]
39. Soluble CD25 in serum: a potential marker for subclinical macrophage activation syndrome in patients with active systemic onset juvenile idiopathic arthritis.
Reddy VV; Myles A; Cheekatla SS; Singh S; Aggarwal A
Int J Rheum Dis; 2014 Mar; 17(3):261-7. PubMed ID: 24417800
[TBL] [Abstract][Full Text] [Related]
40. Performances of the "MS-score" And "HScore" in the diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis patients.
Sag E; Keskin A; Atalay E; Demir S; Cuceoglu MK; Akca UK; Batu ED; Bilginer Y; Ozen S
Rheumatol Int; 2021 Jan; 41(1):87-93. PubMed ID: 33215249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
